核苷酸切除修复
DNA修复
ERCC1公司
顺铂
卡铂
DNA错配修复
奥沙利铂
色素性干皮病
癌症研究
生物
DNA损伤
基底切除修复术
DNA
医学
抗药性
化疗
癌症
遗传学
结直肠癌
作者
Lainie P. Martin,Thomas C. Hamilton,Russell J. Schilder
标识
DOI:10.1158/1078-0432.ccr-07-2238
摘要
Although platinum chemotherapeutic agents such as carboplatin, cisplatin, and oxaliplatin are used to treat a broad range of malignant diseases, their efficacy in most cancers is limited by the development of resistance. There are multiple factors that contribute to platinum resistance but alterations of DNA repair processes have been known for some time to be important in mediating resistance. Recently acquired knowledge has provided insight into the molecular mechanisms of DNA repair pathways and their effect on response to chemotherapy. This review will discuss the most important DNA repair pathways known to be involved in the platinum response, i.e., nucleotide excision repair (NER) and mismatch repair (MMR), and will briefly touch on the role of BRCA in DNA repair. The therapeutic implications of alterations in DNA repair which affect response to platinum in the treatment of patients with malignant disease, such as excision repair cross-complementation group 1 (ERCC1) deficiency and mismatch repair deficiency, will be reviewed.
科研通智能强力驱动
Strongly Powered by AbleSci AI